

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

### VOLUNTARY ANNOUNCEMENT

#### ABSTRACTS AND E-POSTERS OF RESEARCH UPDATES ON KN046 AND KN026 FOR PRESENTATION AT ESMO CONGRESS 2022

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) announces that abstracts and e-posters for the presentation of the research updates on KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) and KN026 (a HER2-targeted bispecific antibody) will be released at the 2022 congress of European Society for Medical Oncology (“**ESMO Congress 2022**”), an influential oncology platform designed in Europe for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world. The abstracts will be available online via the ESMO website at 00:05 CEST (Central European Summer Time) on September 5, 2022 and the e-posters will be presented at ESMO Congress 2022 which will take place from September 9, 2022 to September 13, 2022, all of which will also be presented at the Company’s website at <http://www.alphamabonc.com> correspondingly. Details are set out below:

No.	Name of the Research Study	Presentation No.	Presentation Type
1	A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic NSCLC who have failed first-line platinum-based doublet chemotherapy	1022P	E-poster
2	A phase II study of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic NSCLC who have failed prior EGFR-TKIs	1034P	E-poster
3	Two-year follow-up on KN046 in combination with platinum-based doublet chemotherapy as first-line (1L) treatment for NSCLC: an open-label, multi-center phase II trial	1029P	E-poster
4	The preliminary efficacy and safety of KN026 combined with KN046 treatment in HER2-positive locally advanced unresectable or metastatic gastric/gastroesophageal junction cancer without prior systemic treatment in a phase II study	1210P	E-poster

## **ABOUT KN046**

KN046 is a global innovative PD-L1/CTLA-4 bispecific antibody independently developed by the Group, targeting both PD-L1 and CTLA-4 with a clear structural differentiation to improve localization with the tumor microenvironment and to reduce off-target toxicity. Approximately 20 clinical trials of KN046 in different stages covering more than 10 types of tumors including NSCLC, triple-negative breast cancer, esophageal squamous cell carcinoma, HCC, PDAC and thymic carcinoma have been conducted in China, the United States of America and Australia. The results of these clinical trials have preliminarily shown a favorable safety profile and significant efficacy of KN046 in treatment. Among them, the preliminary results of phase II clinical trials in China indicate promising activity of KN046 for NSCLC, PDAC, HCC and triple-negative breast cancer as a single therapy and in combination therapy with chemotherapy. The Group has published preliminary promising safety and efficacy data of KN046 in patients who have failed prior treatments with immune checkpoint inhibitors. The Group has initiated two pivotal clinical trials in NSCLC, a pivotal clinical trial in PDAC and a pivotal trial in thymic carcinoma. The Group is also exploring cooperation opportunities to conduct clinical trials of KN046 in combination with its business partners' drug candidates, to achieve better therapeutic effects.

The preclinical and clinical trial results of KN046 have shown promising efficacy and indicated that KN046 is able to significantly reduce toxicity to human peripheral system. The Company believes that KN046 has the potential to become a breakthrough in cancer immunotherapy.

## **ABOUT KN026**

KN026 was designed to be a global-level next-generation HER2-targeted therapy. With its innovative structure, it binds simultaneously to 2 distinct clinically validated epitopes of HER2 (paratope II and IV), and maintains a wild type Fc region. This results in (i) a dual blockade of HER2-related signaling pathways, (ii) strengthened binding to HER2 receptors, (iii) a reduction of HER2 proteins on the cell surface, and (iv) increased tumor killing effect through intact antibody-dependent cell-mediated cytotoxicity. These binding mechanisms enable KN026 to have excellent tumor suppressive effect. Several phase I/II clinical trials of KN026 have shown good preliminary efficacy in patients with advanced HER2-positive breast cancer and GC/GEJ. Currently, the pivotal clinical trial of KN026 combined with chemotherapy in patients with HER2-positive GC (including GEJ) who have failed first-line treatment is ongoing in China.

## **ABOUT THE COMPANY**

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. Differentiated in-house pipeline of the Company includes the oncology drug candidates with one approved for marketing by the National Medical Products Administration of China, three in late clinical stage, and two that have received investigational new drug approval or in schedule for the investigational new drug submission. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological new drug candidates that could potentially benefit patients globally.

## DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“CTLA-4”	cytotoxic T-lymphocyte-associated protein 4
“EGFR-TKIs”	epidermal growth factor receptor tyrosine kinase inhibitors, used in the first-line treatment of NSCLC
“ESMO”	European Society for Medical Oncology
“GC”	gastric cancer
“GEJ”	gastroesophageal junction cancer
“HCC”	hepatocellular carcinoma
“HER2”	human epidermal growth factor receptor 2
“HER2-positive”	HER2 immunohistochemistry (IHC) 3+ or HER2 gene amplification
“NSCLC”	non-small cell lung cancer
“PDAC”	pancreatic ductal adenocarcinoma
“PD-L1”	programmed death ligand 1, a protein on the surface of a normal cell or a cancer cell that can attach to programmed cell death protein 1 on the surface of the T-cell that causes the T-cell to turn off its ability to kill the cancer cell

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop, or ultimately market, KN046 and KN026, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, July 29, 2022

*As at the date of this announcement, the Board comprises Dr. XU Ting as the Chairman and Executive Director and Ms. LIU Yang as Executive Director, Mr. XU Zhan Kevin as Non-executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as Independent Non-executive Directors.*